Icahn Gives Name, $200 Million To Medical School

Nov 15 2012 | 2:36am ET

Long before he became a legendary corporate raider and hedge fund manager, Carl Icahn attended medical school. Now, his name will finally appear on a medical diploma—as the name of a medical school.

The Icahn Associates chief, who last year stopped managing outside capital, has pledged $200 million to the Mount Sinai School of Medicine in New York, which will be renamed the Icahn School of Medicine at Mount Sinai. Icahn, who serves on the school's board of directors, has already given $50 million to it, with the other $150 million to come.

Icahn said the gift, which will be primarily used to build research capacity, was influenced by both of his parents: He cited his father's socialist legacy and his mother's dream that her son would become a doctor. "It does help the people that aren't that fortunate," Icahn said of his new namesake.

Icahn also spoke of the two years he spent in medical school at New York University—a school now named for fellow financier Kenneth Langone—at his mother's urging. He "hated" the experience, he said, but added, "My mother would be proud of me today. My name is involved with a medical school."


In Depth

David Yarrow On Growing His Hedge Fund And Shooting The Animals And People Of Africa - As A Photographer

Jul 23 2014 | 6:44am ET

While he’s always been a photographer, recent expeditions to Iceland, Ethiopia...

Lifestyle

Einhorns Busts At WSOP, Finishes In 173rd

Jul 15 2014 | 10:48am ET

Greenlight Capital founder David Einhorn’s World Series of Poker won’t end at...

Guest Contributor

Common Risk Parity Misperceptions

Jul 16 2014 | 11:02am ET

Over the past few years, risk parity has become a component of most investors’...

 

Sponsored Content

    Northern Trust Helps Hedge Funds Navigate Derivatives Regulations

    Jul 8 2014 | 10:48am ET

    The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…

Publisher's Note